中国实用外科杂志

中国实用外科杂志

• 专题笔谈 • 上一篇    下一篇

新辅助治疗用于局部进展期胰腺癌临床评价

张太平，曹    喆，赵玉沛   

  1. 中国医学科学院北京协和医院基本外科，北京 100730 
  • 出版日期:2017-07-01 发布日期:2017-06-30

  • Online:2017-07-01 Published:2017-06-30

摘要：

根治性切除是延长胰腺癌病人生存时间的有效手段，但约40%的病人在初诊时即为局部进展期胰腺癌而失去手术机会。通过制定个体化的新辅助治疗方案，有望使局部进展期胰腺癌降期，从而获得根治性切除的机会。目前，新辅助化疗后序贯放化疗是局部进展期胰腺癌最常见用的新辅助治疗方案，但具体的化疗药物并不统一，吉西他滨联合纳米紫杉醇以及FOLFIRINOX有望成为最佳化疗方案。

关键词: 局部进展期胰腺癌, 新辅助治疗

Abstract:

Application and evaluation of neoadjuvant therapy in locally advanced pancreatic carcinoma        ZHANG Tai-ping，CAO Zhe，ZHAO Yu-pei. Department of General Surgery，Peking Union Medical College Hospital，Peking Union Medical College，Chinese Academy of Medical Sciences，Beijing 100730，China
Corresponding author：ZHAO Yu-pei，E-mail：zhao8028@263.net
Abstract    Radical resection is the effective means to prolong survival time of patients with pancreatic carcinoma. However，40% of the patients are diagnosed with locally advanced pancreatic carcinoma in the first clinic. Individualized neoadjuvant treatment is expected to bring the stage-down of locally advanced pancreatic carcinoma，in order to gain the chance of radical excision. But the specific treatment is still controversial. Neoadjuvant chemotherapy followed by sequential chemoradiotherapy is the most common strategy in the neoadjuvant therapy. Gemcitabine plus nab-Paclitaxel and FOLFIRINOX are expected to be the best chemotherapy regimens.

Key words: locally advanced pancreatic carcinoma, neoadjuvant therapy